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Effect of arginine vasopressin antagonist on renal water
excretion in glucocorticoid and mineralocorticoid deficient rats
SAN-E ISHIKAWA and ROBERT W. SCHRIER
Department of Medicine, University of Colorado School qf Medicine, Denver, Colorado
Effect of arginine vasopressin antagonist on renal water excretion in
glucocorticoid and mineralocorticoid deficient rats. Isolated glucocorti-
coid and mineralocorticoid deficiency have been known to impair renal
water excretion, and both arginine vasopressin (AVP)-dependent and
AVP-independent factors have been implicated. A recently developed
antagonist of the hydroosmotic effect of AVP, [l(/3-mercapto-f3,13-
cyclopentamethylenepropionic acid), 2-0-ethyltyrosine, 4-valine] AVP,
[d(CH2)Tyr(Et)VAVP], was used in the present study to examine the
effect on renal water excretion in three groups of adrenalectomized,
conscious rats. One group (control) was replaced with both glucocorti-
coid (prednisolone, 100 g) and mineralocorticoid [deoxycorticosterone
acetate (DOCA), 500 g] hormones, while the second group (glucocorti-
coid deficient) received only DOCA and the third group (mineralocor-
ticoid deficient) received only prednisolone. The rats were given the
carrier vehicle or the AVP antagonist, 30 pg/kg i.p.; 20 mm later they
were administered 30 mllkg of water orally. The glucocorticoid deficient
rats receiving the vehicle excreted 59.8, 51.3, and 40.0% of the water
load after 1, 5, and 14 days of glucocorticoid deficiency, respectively.
All these values were significantly lower than 94.2% of the water load
excreted by the control rats. When the glucocorticoid deficient rats
received the AVP antagonist, the percent water load excretion in-
creased to 89.3% on day 1, 88.4% on day 5, and 77.0% on day 14
(respectively, as compared to the vehicle rats). Minimal urinary osmo-
lality (Uom) in the glucocorticoid deficient rats receiving the vehicle
alone were 293 mOsm/kg H20 on day 1, 472 mOsm/kg H20 on day 5,
and 558 mOsm/kg H20 on day 14; these values were significantly higher
than the control rats of 161 mOsm/kg H20. The minimal UO.m in the
glucocorticoid deficient rats receiving the AVP antagonist decreased
significantly to 160, 215, and 204 mOsm/kg H20 on day 1, 5, and 14,
respectively. These values were significantly lower than the vehicle
rats. The percent of water load excreted in the mineralocorticoid
deficient rats receiving the vehicle was 87.1% after 10 days of mm-
eralocorticoid deficiency. When the mineralocorticoid deficient rats
received the AVP antagonist, the percent of water load excreted
increased significantly to 156.8% on day 10. Minimal Uosm in the
mineralocorticoid deficient rats was 402 mOsm/kg H20 on day 10, while
the minimal Uosm in the mineralocorticoid deficient rats receiving the
AVP antagonist decreased to 210 mOsm/kg H20 on day 10. The results
indicate that use of the new AVP antagonist clearly implicates AVP in
the impaired water excretion of both glucocorticoid- and mineralocor-
ticoid-deficiency in the conscious rat.
Effet d'un antagoniste de l'arginine-vasopressine sur l'excrétion rénale
d'eau chez des rats déficients en glucocorticoides et minéralocorticoides.
Un deficit isolé en glucocorticoides et en minéralocorticoides est connu
pour géner l'excrétion rénale d'eau, et des facteurs dépendants et
independants de l'arginine vasopressine (AVP) ont été impliques. Un
antagoniste récemment développe de l'effet hydro-osniotique de l'AVP,
Ia [l(acide /3-mercapto-13,f3-cyclopentamethyleneproprionique), 2-0-eth-
yltyrosine, 4-valine] AVP, [d(CH2)5Tyr(Et)VAVP], a ete utilisé dans
cette étude pour examiner l'effet de l'excrétion rénale d'eau dans trois
groupes de rats éveillés, surrénalectomisés. Un groupe (contrôle) avait
un traitement substitutif avec des hormones glucocorticoides (predniso-
lone, 100 g) et minéralocorticoides [deoxycorticosterone acetate
(DOCA), 500 tg], tandis que le second groupe (deficient en glucocorti-
coides) recevait seulement de Ia DOCA et le troisième groupe (deficient
en minéralocorticoides) recevait seulement de Ia prednisolone. Les rats
recevaient le vdhicule ou l'antagoniste de l'AVP, 30 pg/kg par voie
intraperitoneale; 20 mm plus tard us recevaient 30 mI/kg d'eau per Os.
Les rats déficients en glucocorticoides recevant le véhicule excrétaient
59,8, 5 1,3, et 40,0% de Ia charge hydrique aprés 1, 5, et 14 jours de
déficience en glucocorticoides, respectivement. Toutes ces valeurs
dtaient significativement plus basses que les 94,2% de la charge
hydnque excrétde par les rats contrOles. Lorsque les rats déficients en
glucocorticoides recevaient l'antagoniste de l'AVP, le pourcentage
d'excrétion de la charge hydrique s'élevait a 89,3% aujour 1,88,4% au
jour 5, et 77,0% au jour 14 (respectivement, par rapport aux rats traités
par le vdhicule). L'osmolarité minimale urinaire (Uosm) chez les rats
déficients en glucocorticoides recevant le véhicule seul était de 293
mOsm/kg H20 lejour 1,472 mOsm/kg H20 lejour 5,558 mOsm/kg H20
le jour 14; ces valeurs étaient significativement plus dlevées que chez
les rats contrôles, 161 mOsm/kg H20. Um minimum chez les rats
déficients en glucocorticoides recevant l'antagoniste de I'AVP s'est
abaisse significativement a 160, 215, et 204 mOsmlkg H20 auxjours 1,
5, et 14, respectivement. Ces valeurs étaient significativement plus
faibles que chez les rats contrôles. Le pourcentage de charge hydrique
excrété chez les rats déficients en minéralocorticoides recevant le
véhicule était de 87,1% apres lOjours de déficience en minéralocorti-
coides. Lorsque les rats déficients en minéralocorticoides ont recu
l'antagoniste de I'AVP, le pourcentage de Ia charge hydrique excrété
s'est élevé significativement a 156,8% aujour 10. U0., minimal chez les
rats déficients en minéralocorticoides était de 402 mOsm/kg H20 au
jour 10, tandis que Uosm minimum chez les rats déficients en minéralo-
corticoides recevant l'antagoniste s'est abaissé a 210 mOsm/kg H20 au
jour 10. Ces résultats indiquent que l'utilisation du nouvel antagoniste
de I'AVP implique clairement I'AVP dans l'anomalie d'excrétion de
l'eau chez Ic rat éveillé deficient en glucocorticoides ou en
minéralocorticoides.
It has been known for many years that adrenal insufficiency is
associated with impaired water excretion [1—111. Early studies
suggested that the defect in water excretion could be corrected
by extracellular fluid volume expansion or replacement of
glucocorticoid and mineralocorticoid hormones [12—14]. Al-
though this phenomenon has been investigated extensively, the
precise mechanisms for the impairment in water excretion of
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adrenal insufficiency have not been defined fully. This may be
due to the fact that the defect in water excretion in adrenal
insufficiency is multifactorial in nature. In this regard, Boykin
et al [15] and Linas et al [16] from our laboratory have
demonstrated recently that radioimmunoassayable levels of
plasma arginine vasopressin (AVP) are not suppressed in either
the dog or rat with glucocorticoid deficiency during a water load
that suppresses plasma AVP in normal animals to undetectable
levels (<0.5 pg/mi). This defect in water excretion was associat-
ed with a decrease in cardiac output [15], an effect known to
stimulate the nonosmotic release of AVP [17]. Subsequent
confirmatory results were published from another laboratory
in thyroxine-replaced, anterior hypophysectomized rats with
glucocorticoid deficiency [181. In addition, mineralocorticoid
deficiency also has been demonstrated to impair water excre-
tion by mechanisms activated through extracellular fluid vol-
ume depletion [19], which stimulate nonosmotic release of AVP
and impair renal hemodynamics [20]. Although plasma AVP
levels may be increased in these pathological states, reversal of
water retention by using a specific inhibitor of AVP would
provide conclusive and quantitative evidence for the role of
AVP in the impaired water excretion of both glucocorticoid and
mineralocorticoid deficiency. This is particularly important
since studies by Green, Harrington and Valtin [21] and Linas et
al [16] have implicated AVP-independent factors in the defect in
water excretion of glucocorticoid and mineralocorticoid
deficiency.
Such studies are now possible because of a newly developed
antagonist of the hydroosmotic effect of AVP, [l(f3-mercapto-
/3,f3-cyclopentamethylenepropionic acid), 2-0-ethyltyrosine, 4-
valine] AVP, [d(CH2)5Tyr(Et)VAVPI, which was synthesized
and evaluated by Sawyer et al [221 and Manning et al [231. We
also found that d(CH2)5Tyr(Et)VAVP blocks the in vivo hy-
droosmotic effect of exogenous and endogenous AVP in the
absence of changes in solute excretion rate or glomerular
filtration rate (GFR). It also inhibits the in vitro effect of AVP to
stimulate renal medullary and papillary adenylate cyclase activ-
ity [241. The AVP antagonist produces a diuresis in normal rats
which is equivalent to that observed in homozygous Brattleboro
rats suffering from central diabetes insipidus [22]. The purpose
of our experiments was to determine whether or not AVP is
important in the pathogenesis of the impaired water excretion in
glucocorticoid and mineralocorticoid deficiency by using the
AVP antagonist. In addition, whether or not AVP-independent
factors are involved in the defect in water excretion was
examined.
Methods
Male Sprague-Dawley rats weighing 200 to 250 g were used in
this study. Under ether anesthesia the rats were adrenalecto-
mized through bilateral retroperitoneal incisions. After surgery
the animals were allowed free access to 0.9% saline drinking
solution and administered 500 g of deoxycorticosterone ace-
tate(DOCA), i.m., and 100gofprednisolone, s.c.,for7 days
[16]. The doses of prednisolone and DOCA were sufficient to
provide adequate physiological replacement as assessed by
normal gain in body weight over a 3-week period as compared
to control rats. The 0.9% saline was then replaced by deionized
water, and the adrenalectomized rats were divided into three
groups. Specifically, group 1 rats (controls) were given both
DOCA and prednisolone throughout the experiment. In group 2
(glucocorticoid deficient) DOCA, but not prednisolone, was
continued throughout the experiments. In group 3 (mineralocor-
ticoid deficient) prednisolone was continued throughout the
experiments, but DOCA replacement was withdrawn.
Effect of AVP antagonist on renal water excretion in either
glucocorticoid or mineralocorticoid deficiency
Acute oral water loads were performed in glucocorticoid and
mineralocorticoid deficient rats to evaluate the effect of gluco-
corticoid and mineralocorticoid deficiency on renal water ex-
cretion. The water load was administered 2 hr after removal of
food and water in the following manner: The animals were
administered 30 pg/kg of d(CH2)5Tyr(Et)VAVP i.p. or the
vehicle, 0.01 M acetic acid and 0.5% chlorbutanol, and 20 mm
later they were given 30 ml/kg of deionized water by a gastric
tube under light ether anesthesia. The animals were then placed
in individual metabolic cages and allowed to awaken. Spontane-
ously voided urine samples were then collected at 20-mm
intervals for 3 hr. The final urine samples were obtained by
abdominal massage at the end of the experiments. Urine
volume, urinary osmolality (Uosm), and urinary solute excre-
tion were measured and percent water load excreted and
minimal Usm were recorded. Uüsm was measured by freezing-
point depression (model 3R, Advanced Instruments, Inc.,
Needham Heights, Massachusetts).
Seven groups of adrenalectomized rats were studied, and
each group included two subgroups of rats receiving either the
AVP antagonist or the vehicle alone. The groups were as
follows: (1) glucocorticoid and mineralocorticoid replete rats,
which were studied 7 to 21 days after the start of both
glucocorticoid and mineralocorticoid hormone replacement, (2)
glucocorticoid deficient rats after 1 day removal of prednisolone
replacement, (3) glucocorticoid deficient rats after 5 days
without prednisolone, (4) glucocorticoid deficient rats after 14
days without prednisolone, (5) mineralocorticoid deficient rats
after 1 day without DOCA, (6) mineralocorticoid deficient rats
after 5 days without DOCA, and (7) mineralocorticoid deficient
rats after 10 days without DOCA.
Effect of glucocorticoid and rn/n eralocorticoid deficiency on
plasma AVP and plasma osrnolality
To examine the role of plasma AVP in the water retention of
both glucocorticoid and mineralocorticoid deficiency these ex-
periments were performed in glucocorticoid deficient rats on
days 1, 5, and 14: niineralocorticoid deficient rats on days 1, 5,
and 10; and glucocorticoid and mineralocorticoid replete rats.
Deionized water (30 mI/kg) was given orally as described above,
and then blood was taken by decapitation 60 mm after the oral
water load. This time was chosen since our earlier experiments
showed that maximal urine flow and minimal UOsmoccurred
approximately 40 to 80 mm after the oral water load. All blood
samples were taken by heparinized tubes on ice. These samples
were centrifuged at 4°C at 2000 rpm (model PR-i, International
Equipment Co., Division of Damon Corp., Needham Heights,
Massachusetts) for 10 mm. The plasma was then removed and
frozen at —20°C until the time the AVP radioimmunoassay was
performed. The samples were extracted by the method of
Robertson et al [25]. Acetone extracts were prepared by mixing
1.0 ml of plasma with 2.0 ml of cold acetone. After centrifuga-
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Fig. 1. Effect of the AVP antagonist (hatched bars) and vehicle (open
bars) on urinary dilution as assessed by minimal U0C,,, in response to an
acute oral water load in glucocorticoid replete rats and after 1, 5, and
14 days of glucocorticoid deficiency. Values indicate mean SEM.
tion at 3000 rpm for 20 mm, the supernatant is decanted from
the precipitate, thoroughly mixed with 5.0 ml of cold ether, and
the top phase carefully aspirated and discarded. The acetone
remaining in the lower aqueous phase was eliminated under a
stream of air. The precipitations were dissolved in 0.5 ml of
phosphate-buffered saline and then yielded to measure AVP by
radioimmunoas say [26].
The lower limit of detection of the standard curves is 0.5 pg/
ml. A synthetic AVP (Ferring Co., Malmo, Sweden; 400 U/mg)
is used for the standard curves. Intra- and inter-assay coeffi-
cients of variation are 14 and 13.7%, respectively [26]. Oxytocin
crossreacted by less than 0.1% with the AVP antiserum, while
lysine vasopressin showed 10% immunoreactivity when com-
pared with AVP.
Other adrenalectomized rats prepared in the same manner
were used to measure plasma osmolality (Psm). Sixty minutes
after the oral water load, 1.0 ml blood was taken from tail artery
or vein under ether anesthesia. POsm was measured by freezing-
point depression.
Effect of AVP antagonist on GFR in glucocorticoid and
mineralocorticoid deficient rats
Experiments were also performed to ascertain whether the
AVP antagonist affected GFR in either glucocorticoid or mm-
eralocorticoid deficient rats. After induction of anesthesia with
ether, catheters (PE-50, Clay-Adams, Division of Becton, Dick-
inson & Co., Parsippany, New Jersey) were inserted into the
external jugular vein and carotid artery. A suprapubic polyeth-
ylene catheter (PE-100, Clay-Adams) was inserted into the
urinary bladder. The rats then were placed in restraining cages
(Narco Biosystems, Inc., Houston, Texas), and allowed to
awaken. At least 30 mm passed after the animals had awakened
before the experiments were started. The animals were infused
with 0.3% saline containing 1.2 g/dl inulin at a rate of 9 mI/hr
(model 351, Sage Instruments Division, Orion Research Inc.,
Cambridge, Massachusetts) to maintain adequate urine flows
for accurate clearance measurements throughout the experi-
ments. After 60 mm, two 10-mm urine collections were made
and then the AVP antagonist, 30 jsg/kg, or the vehicle were
administered intraperitoneally. Urine samples were then taken
at 10-mm intervals for 90 mm. A 0.5-ml blood sample was taken
from the carotid catheter before the administration of the AVP
antagonist or vehicle and at the end of the experiments. Plasma
and urine inulin concentrations were measured by an autoana-
lyzer (Technicon Instruments Corp., Tarrytown, New York).
Inulin clearance was calculated as an index of GFR. Five
groups of adrenalectomized rats were studied with either vehi-
cle or AVP antagonist; this included all of the above except the
two groups of the glucocorticoid deficient rats on day 5 and the
mineralocorticoid deficient rats on day 5. Each group has two
subgroups of rats receiving either the vehicle or the AVP
antagonist.
Statistics. All values of percent water load excretion, mini-
mal Usm, urinary solute excretion, plasma AVP, POsm, and
inulin clearance were compared between the groups by un-
paired Student's t test. A P value less than 0.05 was considered
significant.
Results
During the 14 days of the experiments, the glucocorticoid and
mineralocorticoid replete rats gained 3.5 0.2 g/day of body
weight, and glucocorticoid deficient rats gained 2.4 0.2 g/day.
The difference in weight gain between these two groups of rats
was significant (P < 0.001). In contrast, mineralocorticoid
deficient rats lost 2.3 0.3 g/day of body weight (P < 0.001
compared to both groups).
Effect of AVP antagonist versus vehicle on water excretion in
glucocorticoid deficient rats
In Figure 1 are shown the effects of the AVP antagonist
versus the antagonist vehicle on minimal Uosm in glucocorticoid
replete and glucocorticoid deficient rats. In the glucocorticoid
replete rats there was a modest difference in minimal UOsm
between the vehicle and AVP antagonist rats (161.3 11.5 vs.
131.9 8.1 mOsm/kg 1120, P < 0.05). This suggested that water
loading (30 mI/kg) does not totally suppress endogenous AVP.
The differences in the minimal Uosm in the glucocorticoid
deplete states between the vehicle and AVP antagonist were
quite evident at day 1(293.3 44.8 vs. 160.1 18.9 mOsm/kg
H20, P < 0.02), day 5 (472.8 43.7 vs. 215.5 24.6 mOsm/kg
H2O, P < 0.001), and day 14 (558.4 37.9 vs. 204.6 30.6
mOsm/kg 1120, P < 0.001). These results demonstrate that
endogenous AVP is an important factor in the defect in urinary
dilution in glucocorticoid deficiency. It is also evident, howev-
er, that AVP independent defect in urinary dilution persists as
minimal Usm in the glucocorticoid deficient state was above
the minimal Uosm in the glucocorticoid replete rats in the
presence of the AVP antagonist (day 1,160.1 18.9 vs. 131.9
8.1 mOsm/kg H2O; day 5, 215.5 24.6 vs. 131.9 8.1 mOsm/
kg 1120, P < 0.005; and day 14, 204.6 30.6 vs. 131.9 8.1
mOsmlkg H2O, P < 0.05). The differences in the percent of
water excreted in the vehicle versus AVP antagonist in the
glucocorticoid deficient rats were 59.8 5.9% vs. 89.3 8.5%
atdayl,P<0.02;51.3±6.7%vs.88.4± 12.4%atday5,P<
p <0.001
P<0.001
P <0.02
P <0.05
Glucocorticoid 1 Day 5 Days 14 Days
replete Glucocorticoid deficient
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GFR, ml/min'
Vehicle 2.70 0.12 (4) 1.88 0.35 (4)
AVP antagonist 2.68 0.11 (4) 1.65 0.09' (4)
P value NS NS
a Values indicate mean SCM. The number in parentheses indicates the number of animals.
b Inulin clearances were not performed after 5 days of glucocorticoid deficiency.
'P < 0.01 versus glucocorticoid replete animals.
1.93 0.40 (4)
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Fig. 2. Effect of the AVP antagonist (hatched bars) and vehicle (open
bars) on urinaly dilution as assessed by minimal U0,,, in response to an
acute oral water load in mineralocorticoid replete rats and after 1, 5,
and 10 days of mineralocorticoid dficiency. Values indicate mean
SCM.
0.02; and 40.0 5.7% vs. 77.0 9.7% at day 14, P < 0.01.
Again, the AVP independent factor is evident as a significant
difference between glucocorticoid replete and glucocorticoid
deplete state persisted in the presence of the AVP antagonist at
day 1(123.5 8.8% vs. 89.3 8.5%, P < 0.02), day 5 (123.5
8.8% vs. 88.4 12.4%, P < 0.05) and day 14 (123.5 8.8% vs.
77.0 9.7%, P <0.005).
The lower Usm and larger percent of water excreted in the
glucocorticoid deficient animals receiving the AVP antagonist
as compared to those receiving the vehicle were not explicable
on differences in solute excretion or GFR between these two
groups (Table 1). As evidence of impaired water excretion, the
Osm was lower in groups of glucocorticoid deficient rats (day 1,
271.0 3.2 m0sm/kg H20, N — 8; day 5, 266.9 3.0 mOsm/kg
1120, N = 8; and day 14, 269.0 4.1 mOsm/kg H20, N = 8, vs.
287.4 1.8 m0sm/kg H20, N = 9, in glucocorticoid replete
rats; all P < 0.005) and the plasma AVP levels were higher in
glucocorticoid deplete rats as compared to glucocorticoid re-
plete rats 60 mm after acute oral water load (day 5, 1.9 0.3 pg/
ml,N= 7;andday 14,2.1 0.2pgIml,N= ll,vs. 0.6 0.1 pg/
ml, N 10; both P < 0.001).
Effect of AVP antagonist versus vehicle on water excretion in
mineralocorticoid deficient rats
In Figure 2 are shown the effect of the AVP antagonist versus
vehicle administration on minimal Uosm as an index of urinary
dilution in mineralocorticoid replete rats and 1, 5, and 10 days
after mineralocorticoid deficiency. Evidence of a difference in
minimal Usm between the vehicle and AVP antagonist was
present after 5 (372.8 18.4 vs. 274.6 32,0 mosm/kg H20, P
< 0.02) and 10 days (402.0 59.9 vs. 210.4 36.2 mosm/kg
1120, P < 0.02) of mineralocorticoid deficiency. These results
demonstrate the importance of endogenous AVP in the im-
paired water excretion after 5 and 10 days of mineralocorticoid
deficiency. It is also evident, however, that an AVP-indepen-
dent defect in urinary dilution persists as minimal Uosm in the
mineralocorticoid replete animals receiving the AVP antagonist
was significantly lower after 1 day (13 1.9 8.1 vs. 239.9 18.3
mosm/kg 1120, P < 0.005), 5 (131.9 8.1 vs. 274.6 32.0
m0sm/kg 1120, P < 0.005) and 10 days (131.9 8.1 vs. 210.4
36.2 mosm/kg H20, P < 0.05) of mineralocorticoid deficiency
and administration of the AVP antagonist. The differences in
percent water excretion in the vehicle versus the AVP antago-
nist group of animals after 10 days (87.1 8.9% vs. 156.8
18.2%, P < 0.005) also emphasized the role of AVP in the
impaired water excretion. There was no statistically significant
impairment in percent water excretion at 1 and 5 days after
removal of mineralocorticoid replacement.
The differences in the minimal Uo and percent water load
excretion between the vehicle and the AVP antagonist-treated
mineralocorticoid deficient rats were not due to differences in
solute excretion or GFR (Table 2). As further evidence of the
impaired water excretion, the POsm was significantly lower after
5 and 10 days of mineralocorticoid deficient rats as compared to
mineralocorticoid replete rats (day 5, 276.0 2.0, N = 6, vs.
287.4 1.8 mosm/kg 1120, N = 9, P < 0.005; day 10, 259.6
5.3, N — 8, vs. 287.4 1.8 m0sm/kg H20; P < 0.001) and the
plasma AVP levels were higher 60 mm after acute oral water
load (dayS, 1.6 + 0.3, N = 8, vs. 0.6 0.1 pg/mI, N = 10, P <
0.01; day 10, 2.5 0.7, N — 10, vs. 0.6 0.1 pglml, P <0.025).
Table 1. Effect of AVP antagonist versus vehicle on solute excretion and GFR in glucocorticoid deficiencya
Glucocorticoid deficient
Hormone replete Day I Day 5 Day 14
Solute excretion, U0,,,V; p.Osm/min
Vehicle 18.4 0.9 (15) 14.9 1.2 (8) 16.0 1.2 (8) 15.2 ÷ 1.3 (8)
AVP antagonist 18.4 + 1.2 (16) 15.! 1.1 (8) 16.4 1.5 (8) 15.0 1.1 (8)
P value NS NS NS NS
P<0.02
NS
P<0.05
11
Mineralocorticoid 1 Day 5 Days 10 Days
replete Mineralocorticoid defictent
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Table 2. Effect of AVP antagonist versus vehicle on solute excretion and GFR in mineralocorticoid deficiencya
Hormone replete
Mineralocorticoid deficient
Day 1 Day 5 Day 10
Solute excretion, U0,,,V; jsOsm/min
Vehicle 18.4 0.9 (15) 18.7 1.7 (10) 21.2 1.6(11) 27.7 4.9 (9)
AVP antagonist 18.4 1.2 (16) 18.2 1.0 (9) 22.1 1.3 (9) 23.1 1.9 (9)
P value NS NS NS NS
GFR, mllmi&'
Vehicle 2.70 0.12 (4) 2.12 0.46 (4) 1.65 0.l6c (4)
AVP antagonist 2.68 0.11 (4) 1.80 0.21d (4) 1.50 0.09c (4)
P value NS NS NS
a Values indicate mean SEM. The number in parentheses indicates the number of animals.
b Inulin clearances were not performed after 5 days of mineralocorticoid deficiency.
P < 0.01 versus mineralocorticoid replete animals.
' P < 0.02 versus mineralocorticoid replete animals.
Discussion
Adrenal insufficiency has been known for many years to be
associated with impaired water excretion in both man and
animals [1—16, 18—211. In recent years the suggested mecha-
nisms for this impaired water excretion have included glucocor-
ticoid-mediated persistent AVP release in the presence of
hypoosmolality [271, increased water permeability in the col-
lecting duct secondary to glucocorticoid deficiency [5], extra-
cellular fluid (ECF) volume-mediated AVP release [7, 12] and
AVP-independent factors of undefined nature [211. In a recent
series of studies in the conscious, adrenalectomized dog [15, 19,
20] and rat [16, 18, 21], the separate role of giucocorticoid and
mineralocorticoid deficiency to impair water excretion has been
evaluated and both hormones appear to be of physiological
importance in the normal modulation of renal water excretion.
Although measurements of persistent levels of plasma AVP in
the presence of plasma hypoosmolality have implicated the
nonosmotic release of AVP in the impaired water excretion
with both glucocorticoid [15, 16, 18] and mineralocorticoid
deficiency [201, the mechanisms for the AVP release have been
suggested to be different. Specifically, ECF volume depletion is
an important factor in the inappropriately elevated levels of
AVP in the mineralocorticoid deficient state and this defect is
no longer detectable in glucocorticoid replete, mineralocor-
ticoid deficient animals who avoid ECF volume depletion by
drinking saline solution [19]. In contrast, ECF volume depletion
is not a feature of the elevated plasma levels of AVP and the
impaired water excretion in the glucocorticoid deficient animal
[15, 16]. Both a central effect of glucocorticoid deficiency [281
and a baroreceptor-mediated release of AVP secondary to a fall
in cardiac stroke volume due to glucocorticoid deficiency [15,
16] have been suggested. In addition, there is now evidence
from studies performed in homozygous Brattleboro rats that
AVP independent factors are involved in the impaired water
excretion secondary to both glucocorticoid and mineralocor-
ticoid deficiency [21].
The recent development by Sawyer et al [22] and Manning et
al [23] of an analogue of AVP which exerts a potent inhibitory
effect on the hydroosmotic action of AVP has allowed for the
further examination of the role of endogenous AVP in patholog-
ical states of water retention. The AVP antagonist inhibits
completely the in vivo effect of supraphysiological doses of
AVP to concentrate the urine of the conscious water diuresing
rat [24] and generates a water diuresis in the hydropenic rat
which is comparable to the homozygous Brattleboro rat [221.
The induced diuresis with the AVP antagonist was not found to
be associated with either a rise in solute excretion or GFR [24].
Moreover, the AVP antagonist has been shown to block the in
vitro effect of AVP to stimulate adenylate cyclase in rat renal
medullary and papillary tissue [24] and rat papillary collecting
duct (unpublished data). This specific and potent AVP antago-
nist was therefore used in this study to further explore the role
of endogenous AVP in the impaired water excretion associated
with glucocorticoid and mineralocorticoid deficiency.
The present results provide strong confirmatory evidence for
the role of plasma AVP in the impaired water excretion
associated with glucocorticoid and mineralocorticoid deficien-
cy. It was heretofore possible that the radioimmunoassayable
plasma levels of AVP, which has been detected at a time when
the osmoreceptor mediated release of AVP should have caused
suppression of plasma AVP to undetectable levels (<0.5 pg/mi),
were not exerting a physiological effect on renal water excre-
tion. Such a discrepancy between biological effect and radioim-
munoassayable titer of AVP has precedents and could occur
because of the presence of biologically inactive hormone,
impaired AVP receptor binding or perhaps abnormalities in
postreceptor events [29]. While this study does not exclude the
presence of any such defects, it is clear that antagonism of
biologically active AVP did occur and resulted in a marked
improvement in water excretion both in glucocorticoid and
mineralocorticoid deficient animals. The AVP-mediated impair-
ment in water excretion was detectable as early as after 1 day of
glucocorticoid deficiency using the AVP antagonist. This find-
ing is quite compatible with the early studies of Linas et al [161
in which adrenalectomized rats with a normal hypothalomo-
pituitary axis, but not homozygous adrenalectomized Brattle-
boro rats, demonstrate a defect in water excretion after 24 hr of
glucocorticoid deficiency. In contrast, evidence of AVP in-
volvement in the impaired water excretion of mineralocorticoid
deficiency was not unequivocally present until 5 days after
mineralocorticoid deficiency. This finding is compatible with
the period of time that may be necessary for aS to 10% decrease
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in ECF volume depletion to occur secondary to mineralocor-
ticoid deficiency and renal sodium loss; such a 5 to 10%
decrement has been found to be necessary in the rat to stimulate
the nonosmotic release of AVP [30].
In addition to demonstrating the biological efficacy of the
AVP antagonist in the pathological states of water retention and
further incriminating AVP in the impaired water excretion of
glucocorticoid and mineralocorticoid deficiency, the present
results provide further evidence for the role of AVP-indepen-
dent factors in the impaired water excretion associated with
adrenocortical hormone deficiency. Green, Harrington, and
Valtin [211 initially suggested such a role of non-AVP factors
when they demonstrated improvement in urinary dilution and
water excretion in adrenalectornized Brattleboro rats by gluco-
corticoid and mineralocorticoid replacement therapy in physio-
logical doses. While the Brattleboro rat has abnormalities, in
addition to AVP deficiency, which may temper interpretations
when compared to the intact rat, the present results using the
AVP antagonist in the intact rat strongly support these early
conclusions by Green, Harrington, and Valtin [21] as well as
Linas et al [16]. Lastly, as previously shown in the intact rat
[24] the effect of the AVP antagonist to improve renal water
excretion in states of adrenocortical hormone deficiency were
not due either to an increase in solute excretion or GFR. As in
early studies nonsuppressible radioimmunoassayable titers of
AVP were demonstrable in spite of hypoosmolality in both
glucocorticoid and mineralocorticoid deficient animals.
In summary, these studies have demonstrated the efficacy of,
to our knowledge, a new and exciting AVP antagonist in the
pathological states of water retention associated with glucocor-
ticoid and mineralocorticoid deficiency. Clinical improvement
of abnormal states of water retention as well as provision of
important pathophysiological information regarding AVP de-
pendent and AVP independent factors in abnormal water reten-
tion might be expected by the future use of this AVP antagonist
in a wide variety of endocrine, cardiac, hepatic, renal hemody-
namic, and drug-induced states of impaired water excretion.
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